Navigation Links
VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
Date:4/16/2009

First Selective TLR8 Agonist to Advance for Treatment of Allergy

SAN DIEGO, April 16 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and inflammatory diseases, announced today that it has initiated a Phase I clinical trial of VTX-1463, a selective intranasal TLR8 agonist for the treatment of allergic rhinitis. The objectives of this trial will be to assess safety, tolerability and pharmacokinetics of single and multiple ascending doses of VTX-1463 in approximately 30 healthy volunteers. The trial is being conducted in the Netherlands.

"We are pleased to advance VTX-1463 into the clinic," said Dr. Robert Hershberg, Executive Vice President and Chief Medical Officer at VentiRx. "This is another milestone for our TLR8 effort as this is the second clinical program initiated in the last six months." VTX-2337 began Phase I clinical trials in cancer patients in November 2008.

VTX-1463 is a small molecule TLR8 agonist that is being developed as a stand-alone agent for the treatment of allergic rhinitis. In preclinical animal studies, this compound has been shown experimentally to dramatically reduce allergic responses without requiring the concomitant administration of allergen. As such, it represents a potential prophylactic and/or therapeutic solution for allergic diseases, regardless of the antigen responsible for the allergic response. The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-1463 in healthy volunteers and will help define the appropriate dose(s) for a proof of concept clinical study in allergic patients later this year.

"VTX-1463 is the first selective TLR8 compound to reach the clinic for allergy," said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. "Allergic diseases affect approximately twenty percent of the overall population. Based on strong preclinical data, we expect that modulation of the innate immune response will provide a benefit to people that suffer from these diseases."

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer, respiratory and inflammatory diseases. The Company's initial focus is on developing small molecule TLR-based product candidates for oncology and allergy. VentiRx is a privately held organization headquartered in San Diego with operations in Seattle. For additional information, please visit www.ventirx.com.


'/>"/>
SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
3. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
4. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
5. Strativa Pharmaceuticals Provides Product Pipeline Update
6. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
8. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
9. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... , May 24, 2016 ... Markt gebracht, die es Ärzten erlaubt, ihre Expertise ... behandeln: MDLinking kombiniert Live Streaming mit einer Instant-Messaging-Funktion ... zu kommunizieren. Mediziner in Europa, Afrika, Asien und ... bereits für die Plattform registriert. Information ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... seen a significant spike in their clients' employee participation for their wellness initiatives. ... screening by implementing a high-deductible health plan with outcome-based deductible incentives. As a ...
(Date:5/25/2016)... Jersey (PRWEB) , ... May 25, 2016 , ... ... technology firm will be selling the device branded as Stern’s Real Time Monitoring ... geared to bedbugs to the hotel and motel industry, colleges for use in dormitories, ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhishLine, the best-in-class, enterprise ... company as Vice President of Sales. Cifolelli’s primary responsibilities include management of ... the rapidly expanding field of organizational social engineering. , “We are delighted ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and Communications ... the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of Directors ... , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... How to Write ... Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major ... human error will ever be totally eliminated, many human performance problems can be prevented. ...
Breaking Medicine News(10 mins):